Where does Kardiolytics Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Kardiolytics Inc. ranks #41,184 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Kardiolytics Inc. hold?

Kardiolytics Inc. holds 6 US utility patents granted between 2022 and 2025, spanning 6 technology areas.

What is Kardiolytics Inc.'s Innovation Score?

Kardiolytics Inc. has an Innovation Score of 40.2 out of 100 (top 36% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Kardiolytics Inc. focus on?

Kardiolytics Inc.'s top technology area is G06T (Image Data Processing OR Generation, IN General) with 6 patents, ranking #1,896 of 6,389 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Kardiolytics Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Kardiolytics Inc..

What does claim depth mean for Kardiolytics Inc.'s patents?

Kardiolytics Inc.'s patents average 8.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Kardiolytics Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Kardiolytics Inc.

USPTO PatentsView assignee record - 6 granted patents across 6 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: G06T (Image Data Processing OR Generation, IN General).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Kardiolytics ranks #41,184 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 6 technology areas.

#41,184
of 49,997 US assignees by volume: Top 36%
by Innovation Score (40.2/100): 8.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R41184 · US Corporation #41,184 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-PAR · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 6 grants
LOWER-Q #41,184/49,997
PHOTO-FINISH Kang Na Hsiung…
CPC-NARROW G06T · 6 areas
INNOV-PAR 40.2/100
CLAIMS-PAR 8.0 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2022–2025 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Kang Na Hsiung Enterprise Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Kardiolytics’s 40.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.7 pts (17%) Velocity 20.0 pts (50%) Breadth 8.7 pts (22%) Claim depth 4.8 pts (12%)

Qualcomm Incorporated · highest

85
Kardiolytics · this assignee

40
3D Lighting… · lowest

7

What this shows Kardiolytics's Innovation Score is 40.2/100 (top 36% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Kardiolytics?

Each dot is one of Kardiolytics’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Kardiolytics’s own 8.0 claims/patent is at or below the 11.7 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Kardiolytics vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Kardiolytics's grants concentrate

Kardiolytics Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under G06T (Image Data Processing OR Generation, IN General). Peak complete grant year is 2022 (2 grants) versus a trough of 1 in 2023. By volume, Kardiolytics sits between Kang Na Hsiung Enterprise Co., Ltd. and Katena Products, Inc..

Kardiolytics's three-year grant acceleration

Kardiolytics Inc. shows 5 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Kang Na Hsiung En…

6
Kangpu Biopharmac…

6
Kapito

6
Kappler Med + Org

6
Karltex Machine

6
Kashiv Pharma

6
Katayama Kogyo

6
Katena Products

6
Kardiolytics ◀

6

What this shows Kardiolytics holds 6 patents at rank #41,231, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Kardiolytics

By rank, the assignees closest to #41,231 in granted patent volume.

Leaders in G06T (Image Data Processing OR Generation)

Other assignees with the most granted patents in Kardiolytics's primary technology class.

Kardiolytics's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 36% higher than 64% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

Kardiolytics Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	2	33.3%
2023	1	16.7%
2024	2	33.3%
2025partial year	1	16.7%

Which technologies does Kardiolytics Inc. patent most?

G06T - Image Data Processing OR Generation, IN General 6

A61B - DIAGNOSIS; SURGERY; Identification 4

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 2

G06V - Image OR Video Recognition OR Understanding 2

G06F - Electric Digital Data Processing 1

G06N - Computing Arrangements Based ON Specific Computational Models 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Kardiolytics Inc.'s patent record in context - here's where to go next.

Kardiolytics Inc.'s lead technology class is G06T (Image Data Processing OR Generation, IN General), 100% of its portfolio - see every assignee active in that class. Explore G06T
Ranked #41,184 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Kardiolytics Inc. against Kang Na Hsiung Enterprise Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 40.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.